Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Top Cited Papers
Open Access
- 13 February 2003
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 348 (7) , 601-608
- https://doi.org/10.1056/nejmoa020888
Abstract
Treatment with infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor, can result in the formation of antibodies against infliximab. We evaluated the clinical significance of these antibodies in patients with Crohn's disease.Keywords
This publication has 17 references indexed in Scilit:
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialPublished by Elsevier ,2002
- Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience.Inflammatory Bowel Diseases, 2001
- Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patientsAmerican Journal of Gastroenterology, 2001
- Infliximab in Crohn's Disease: First Anniversary Clinical ExperienceAmerican Journal of Gastroenterology, 2000
- Clinical Experience With Infliximab Therapy in 100 Patients With Crohn's DiseaseAmerican Journal of Gastroenterology, 2000
- Infliximab and Methotrexate in the Treatment of Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's diseaseGastroenterology, 1999
- Review article: safety of infliximab in clinical trialsAlimentary Pharmacology & Therapeutics, 1999
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseNew England Journal of Medicine, 1997